Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

TAK-960

Known as: PLK1 Inhibitor TAK-960, Polo-like Kinase 1 Inhibitor TAK-960 
An orally available, Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor TAK-960 selectively… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundPolo-like kinase 1 (Plk1) is a serine/threonine kinase that is a key regulator of multiple stages of mitotic… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
The cytotoxicity of ionizing radiation depends on the cell cycle phase; therefore, its pharmacological manipulation, especially… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2015
2015
Sarcomas are rare cancers and the current treatments in inoperable or metastatic disease have not been shown to prolong survival… Expand
2013
2013
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2011
Highly Cited
2011
Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase involved in key processes during mitosis. Human PLK1 has been… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4